Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 11/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17511817 | 0.92 | HCAR3 (0.58) | HCAR3TSHRCASP6LMNAMAPT | |
| SCHEMBL28545324 | 0.86 | CASP6 (0.50) | HCAR3TSHRCASP6LMNA | |
| SCHEMBL177446 | 0.86 | HCAR3 (0.53) | HCAR3TSHRCASP6LMNA | |
| SCHEMBL4175596 | 0.85 | CASP6 (0.58) | HCAR3TSHRCASP6LMNAMAPT | |
| SCHEMBL16129686 | 0.84 | CASP6 (0.54) | HCAR3TSHRCASP6LMNA | |
| SCHEMBL28748754 | 0.82 | HCAR3 (0.51) | HCAR3TSHRCASP6LMNA | |
| SCHEMBL16129652 | 0.82 | ALDH1A1 (0.53) | TSHRLMNAALDH1A1MAPTMEN1 | |
| SCHEMBL13264670 | 0.80 | CASP6 (0.55) | HCAR3TSHRCASP6LMNAMAPT | |
| SCHEMBL6476753 | 0.80 | TSHR (0.51) | HCAR3TSHRCASP6LMNA | |
| SCHEMBL6950169 | 0.78 | CASP6 (0.55) | HCAR3TSHRCASP6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| WO-2014147182-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052898-A1 | NOVEL COMPOUNDS | AADAC, NAT1, CCNA1 | HCAR3 2562/4885TSHR 3456/4885CASP6 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.